123 results about "Eosinophilic Granulocyte" patented technology

The invention belongs to the technical field of biological medicines, and particularly relates to a pyruvate preparation for treating asthma and a preparation method of the pyruvate preparation. The pyruvate preparation is prepared from the following components in parts by weight: 10 to 12 parts of pyruvate, 10 to 12 parts of sodium chloride, 0.5 to 1 part of citric acid and 500 parts of water for injection. The pH value of the pyruvate preparation is 6 to 7. The pyruvate preparation is used for daily management of asthma patients, the purpose of inhibiting asthma is achieved by controlling increase of the number of inflammatory cells such as eosinophilic granulocytes and reducing inflammatory reaction, the effect of the pyruvate preparation is close to that of similar hormone medicine dexamethasone, and the effect of the pyruvate preparation is improved while the treatment purpose is achieved. The dependence and side effects of patients on hormone drugs are reduced.

The present invention is directed to orally administered compositions of topically acting corticosteroids for the treatment of inflammation of the gastrointestinal tracts such as eosinophilic esophagitis. The present invention also provides a method for treating conditions associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention as orally disintegrating tablets comprising a topically active corticosteroid adsorbed onto a pharmaceutically acceptable carrier such as silicified microcrystalline cellulose.

The present disclosure provides methods of treating an immune-mediated disease in a subject in need thereof. The present disclosure provides methods of treating atopic dermatitis in a subject in need thereof. The present disclosure provides methods of treating moderate-to-severe atopic dermatitis in a subject in need thereof. The present disclosure provides a method of treating atopic dermatitis (AD) in a subject in need thereof, comprising selecting a subject having AD and an elevated level of at least one biomarker selected from the group consisting of thymus and activation-regulated chemokine (TARC), interleukin-5 (IL-5), eosinophil count, and lactate dehydrogenase (LDH) relative to a control.

The invention belongs to the field of small molecule compound medicines, and relates to application of an APE1 inhibitor in preparation of a medicine for treating asthma. The invention provides a novel treatment strategy of asthma, discovers a new target APE1 for treating asthma, realizes an effective treatment effect on asthma by using an APE1 inhibitor C10 compound, can remarkably inhibit the inflammatory cell activity such as mast cells, eosinophilic granulocytes and lymphocytes of asthma, and can remarkably inhibit the inflammatory cell activity of mice lung pathology observation. The C10 compound disclosed by the invention has obvious relieving and relieving effects on lung pathological changes of asthma mice, so that the C10 compound can be clinically used for preventing or treating asthma, and has the industrial advantages of small molecular weight and simple synthesis process.

A computer-implemented method for diagnosing diseases that affect the morphological characteristics and the cytoplasmic complexity of blood cells, the method comprising: a) obtaining blood parameters from at least one patient, the blood parameters comprising at least two measured properties of individual cells from full blood analysis, the individual cells comprising leukocytes, the measured properties of the leukocytes comprising the size and granularity of the cytoplasm and the structure of the cell nucleus; b) creating at least one scatter plot, each axis of the scatter plot comprising a different measured property of the individual cells; c) ascertaining at least one cluster in at least one scatter plot, the clusters comprising the subpopulations of leukocytes, the subpopulations comprising monocytes, lymphocytes, basophils, neutrophils and eosinophils; d) combining the property elements of the ascertained clusters to form a 1-dimensional global vector, the arrangement of the property elements in the global vector comprising an arrangement by associated cluster; e) reducing the dimension of the global vector; f) diagnosing at least one disease by means of an ensemble, the ensemble comprising at least one machine learning model and at least one deep learning model, the at least one machine learning model receiving at least one reduced global vector as an input variable and the at least one deep learning model receiving at least one scatter plot image as an input variable; and g) automatically generating a report which comprises at least one result of the diagnosis of at least one disease.

The invention belongs to the field of small molecule compound medicines, and relates to application of an APE1 inhibitor in preparation of a medicine for treating nasosinusitis. The present application finds a new target APE1 for treating nasosinusitis, and achieves effective treatment of nasosinusitis by an APE1 inhibitor (including a C10 compound), in which the C10 compound shows a very excellent therapeutic effect, significantly inhibits pathological symptoms of nasosinusitis, including relieving Th2 inflammation, reducing eosinophilic granulocyte infiltration, improving nasal barrier integrity damage, and preventing or treating nasosinusitis. And the nasal mucosa neovascularization is prevented by inhibiting the generation of VEGF and other cell factors, and the inflammatory response of chronic nasosinusitis is effectively relieved. In addition, the C10 compound is simple in structure and easy to synthesize, has good patent medicine characteristics, and has good industrialization prospects.

The invention belongs to the technical field of biology, and particularly relates to a reagent and a kit for detecting eosinophilic granulocyte chronic sinusitis with nasal polyp. The detection reagent comprises the following components: a substance which is used for detecting the Galectin-10 protein (Charcot-Leyden Crystal, CLCs) in a crystalline state, and a detection reagent which is used for detecting the Galectin-10 protein (Charcot-Leyden Crystal, CLCs) in the crystalline state. The reagent for detecting CLCs comprises a mixture of eosin, glacial acetic acid and water. The mass volume ratio of eosin to glacial acetic acid is 1: (1-50) g / mL, and the volume ratio of glacial acetic acid to water is 1: (2-100). According to the invention, the reagent capable of efficiently detecting the CLCs is found for the first time, and the CLCs is a biomarker of the eosinophilic chronic sinusitis with nasal polyp, so that the detection reagent for the eosinophilic chronic sinusitis with nasal polyp is provided. By detecting CLCs, eosinophilic granulocyte chronic sinusitis with nasal polyp can be predicted, and the method is simple, convenient and fast and has good prediction performance.

The present disclosure relates to methods of treating a subject suffering from an eosinophil-associated chronic obstructive pulmonary disease (COPD) or asthma-COPD overlap (ACO) using compounds that bind to CD131 and inhibit signalling of interleukin (IL) 3, IL-5 and granulocyte-macrophage colony stimulating factor (GM-CSF).

The invention discloses a blood routine examination and immunochromatography combined detection reagent card, and belongs to the technical field of medical detection, the blood routine examination and immunochromatography combined detection reagent card comprises a reagent card body, the reagent card body comprises a detection counting area, a reagent liquid filling area and a sampling area, the sampling area is used for accommodating a sample and pre-diluting the sample, the reagent liquid filling area is used for treating and diluting the sample, and the detection counting area is used for counting the detection counting area. The detection counting area comprises a red blood cell counting square groove, a white blood cell counting square groove and a blood platelet counting square groove. Five groups of neutrophil, lymphocyte, mononuclear cell, eosinophilic granulocyte and basophilic granulocyte in leukocyte are realized, and promotion of a basic POCT instrument can be promoted by matching with other necessary blood routine parameters and CRP, SAA, glycosylated hemoglobin and other parameters. The operation of a user is convenient, the joint detection test of blood routine examination and immunochromatography items can be fully automatically completed by one reagent card and the immunochromatography card, and extra dilution of a sample is not needed.

The application discloses application of volatile oil of Citrus aurantium in preparation of a medicine for preventing and treating allergic rhinitis. The application proposes that the volatile oil of Citrus aurantium can significantly reduce the levels of mast cell factors IL-1beta and TNF-alpha, and can also significantly reduce the levels of inflammatory factors IL-13 and IL-4 in mice, reduce inflammatory cell infiltration, and reduce eosinophilic granulocyte increase and gland hyperplasia. The application proposes that the volatile oil of Citrus aurantium has great potential as a medicinal and edible raw material for treating allergic rhinitis. The application also proposes that the volatile oil of Citrus aurantium can significantly improve symptoms such as sneezing, runny nose, and nasal itching of mice caused by allergic rhinitis, and the symptoms seriously affect the life of patients.

Disclosed in the present invention is the use of a recombinant protein CCL11 in the treatment of malignant pleural effusions. Specifically, the present invention provides a method for treating and / or relieving malignant pleural effusions by means of intrapleural injection of the recombinant protein CCL11. The present invention first found that CCL11 can relieve MPEs by means of increasing eosinophilic granulocytes in the thoracic cavity. An MPE animal model is constructed, and intrapleural injection of the recombinant protein CCL11 remarkably increases eosinophilic granulocytes in the thoracic cavity, and meanwhile, obviously relieves MPEs.

The invention discloses an application of thermal sensitive Sibestein granules in treating / or preventing asthma, and belongs to the technical field of biological medicines. The invention finds that the thermal sensitive Sibestein granules can reduce the total number of cells and the number of eosinophilic granulocytes, neutrophil granulocytes and lymphocytes in asthma mice BALF, reduce the level of cell factors in asthma mice BALF and IgE in serum, reduce exudation of inflammatory substances in airway and alveolar tissues of asthma mice and infiltration of inflammatory cells, improve the lesion degree of lung tissues, and improve the curative effect of the lung tissues. The action mechanism may be related to regulation and control of MAPK / NF-kappa B signal channel related protein expression, so that inflammatory response and cell apoptosis are inhibited, and airway inflammation of mice is relieved.

The invention relates to the technical field of compositions, and particularly discloses a composition for assisting in improving eosinophilic esophagitis and application of the composition. The composition for assisting in improving eosinophilic esophagitis provided by the invention comprises an iron source, a zinc source and L-carnitine. By optimizing the components of the composition and specifically limiting the proportion of the iron source, the zinc source and the L-carnitine in the composition, esophageal epithelial hyperplasia can be effectively reversed, the number of bifidobacteria is increased, the number of enterobacter and esophageal tissue eosinophilic granulocytes is reduced, the level of IL-13 cell factors is reduced, and the curative effect is improved. Further, the effect of remarkably assisting in improving eosinophilic granulocytic esophagitis is achieved.

The invention discloses an immune-engineered mitochondrial nMITO as well as a preparation method, application and an evaluation method thereof, and relates to the technical field of asthma treatment. According to the application of the immune-engineered mitochondrial nMITO in preparation of the medicine for treating asthma, through the specific immune regulation function of the nMITO, local overactivated immune cells (such as eosinophilic granulocytes and Th2 cells) of an airway are regulated in a targeted mode, abnormal release of proinflammatory factors (such as IL-4, IL-5 and IL-13) is inhibited, meanwhile, activation of an anti-inflammatory signal channel is promoted, and the anti-inflammatory effect is improved. Therefore, the steady state of the airway immune microenvironment is recovered, accurate and efficient intervention on chronic asthma inflammation is achieved, the aims of improving the treatment effect, reducing adverse reactions and reducing disease relapse are finally achieved, and a brand new technical scheme is provided for clinical treatment of asthma.

Methods for treating eosinophilic esophagitis in a pediatric subject are provided. In one aspect, the method comprises administering to the subject one or more doses of an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof.

The invention relates to the technical field of artificial intelligence, and provides an eosinophilic gastroenteritis typing system and method based on multi-modal data, and the method comprises the steps: obtaining a digestive endoscopy image, an ultrasonic endoscopy image, a CT examination image and clinical manifestation data of a to-be-detected person collected in the same time period; the gastrointestinal mucosa lesion state is recognized through a digestive endoscopy image and is represented by numerical features; identifying the abnormal thickening condition of each film layer structure of the gastrointestinal wall through an ultrasonic endoscope image, and representing the abnormal thickening condition by numerical features; lesion hierarchical distribution is judged through an ultrasonic endoscope image, and numerical feature representation is carried out; determining seroperitoneum and intestinal wall thickening conditions through a CT examination image, and performing numerical characteristic representation on the seroperitoneum and intestinal wall thickening conditions; clinical symptom features are obtained through the clinical manifestation data and are represented by numerical features; generating a feature vector based on multi-modal data by using each numerical value feature representation; and inputting the feature vectors into a dynamic typing prediction model to realize the typing prediction of eosinophilic gastroenteritis, thereby improving the accuracy of auxiliary diagnosis and evaluation.

A method of treating a tissue exhibiting eosinophil-related inflammation in a subject is disclosed. The method includes administering a composition to the subject that contains a therapeutically effective amount of a polymer and a pharmaceutically acceptable excipient. The polymer is formed from an acidic amino acid, e.g., aspartate and / or glutamate, or a pharmaceutically acceptable salt thereof. The polymer has an average molecular weight of at least about 5 kDa. The polymer binds to one or more eosinophil granule proteins in the tissue to neutralize the eosinophil granule proteins and treat the eosinophil-related inflammation.

The invention provides a method for detecting eosinophilic granulocyte peroxidase and application thereof, and relates to the technical field of biological detection.The method comprises the steps that a respiratory tract sample and a sample treatment reagent are mixed, dispersion treatment and centrifugation are conducted, supernatant is taken, and a to-be-detected sample is obtained; carrying out magnetic particle chemiluminescence detection on a to-be-detected sample, and judging the content of eosinophilic granulocyte peroxidase according to a luminescence signal value obtained by detection, the final pH value of the reaction system is 8.0-12.0 according to the detection of a light-emitting signal value; the sample treatment reagent is an aqueous solution containing 0.06-0.12% w / v of a reducing agent. The technical prejudice that the EPX detection is interfered by the peroxidase activity of the EPX in the prior art is overcome; and meanwhile, the mucus is uniformly dispersed through dispersion treatment by virtue of a sample treatment reagent containing a reducing agent, so that high-sensitivity and high-specificity full-automatic detection of the respiratory tract sample EPX is realized on the magnetic particle chemiluminescence platform for the first time.

The invention belongs to the field of biological medicine, and relates to an anti-IL-5 antibody, and a pharmaceutical composition and application thereof. Specifically, the invention relates to an anti-IL-5 antibody or an antigen binding fragment thereof, the anti-IL-5 antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises complementarity determining regions HCDR1 to HCDR3, the light chain variable region comprises complementarity determining regions LCDR1 to LCDR3, the amino acid sequence of the HCDR1 is shown as SEQ ID NO: 3, the amino acid sequence of the HCDR2 is shown as SEQ ID NO: 4, and the amino acid sequence of the HCDR3 is shown as SEQ ID NO: 5, the amino acid sequence of the LCDR1 is as shown in SEQ ID NO: 6, the amino acid sequence of the LCDR2 is as shown in SEQ ID NO: 7, and the amino acid sequence of the LCDR3 is as shown in SEQ ID NO: 8. The antibody disclosed by the invention can be specifically combined with IL-5, has relatively high affinity, and has good potential for treating or preventing diseases caused by eosinophilic granulocytes higher than normal level.

The present invention provides an antibody or a conjugated fragment of a citrulline-containing epitope used for the treatment or prevention of diseases associated with the release of extracellular traps from cells, such as neutrophil extracellular trap (NET)-associated pathology (NET-associated pathology) or eosinophil extracellular trap (EET)-associated pathology (EET-associated pathology), and provides a method comprising administering at least one dose of the antibody at a specific concentration. The present invention also provides the method itself. NET-related pathologies include systemic lupus erythematosus (SLE), lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), Sjögren's disease, antiphospholipid syndrome, Behçet's disease, spondylitis, spondyloarthritis, multiple system atrophy, Parkinson's disease, Lewy body dementia, asthma, allergic rhinovirus exacerbated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulomatous uveitis, granulomatous uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, or wound healing in diabetes, cancer, cancer metastasis, or wound healing in diabetes, cancer, cancer metastasis, and in This includes other NET-related pathologies, such as the health of transplanted organs in vivo or ex vivo.The present invention also relates to wound healing in SLE, lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), Sjögren's disease, antiphospholipid antibody syndrome, Behçet's disease, spondylitis, spondyloarthritis, multiple system atrophy, Parkinson's disease, Lewy body dementia asthma, allergic rhinovirus exacerbating asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulomatous uveitis, granulomatous uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, thrombotic disease, cardiovascular disease, or diabetes, cancer, cancer metastasis, or wound healing in diabetes, cancer, cancer metastasis, and in vivo or ex vivo The present invention provides pharmaceutical compositions and methods for treating and preventing NET-related pathologies, including other NET-related pathologies such as the health of transplanted organs in vivo. NET-related pathologies include eosinophilic diseases or conditions of the skin, respiratory eosinophilic diseases or conditions, gastrointestinal eosinophilic diseases or conditions, allergic diseases or conditions, or eosinophilic diseases or conditions such as helminthic, fungal, viral or bacterial infections.

The present disclosure, relates, in general, to methods of treating eosinophilic esophagitis (EOE) using an antibody specific for thymic stromal lymphopoietin (TSLP).

The invention relates to the field of biotechnology and in vitro diagnosis, in particular to an anti-eosinophilic granulocyte peroxidase monoclonal antibody and application thereof. The antibody provided by the invention can directly and specifically capture eosinophilic granulocyte peroxidase with enzyme activity, and is used for biological research and clinical diagnosis of eosinophilic granulocytes. The monoclonal antibody for resisting eosinophilic granulocyte peroxidase is prepared by the following steps: taking recombinant eosinophilic granulocyte peroxidase as an immunogen to immunize a Balb / c mouse, then fusing the spleen with a myeloma cell NS1, and screening and purifying to obtain the monoclonal antibody for resisting eosinophilic granulocyte peroxidase. The prepared monoclonal antibody for resisting the eosinophilic granulocyte peroxidase specifically recognizes the epitope of the eosinophilic granulocyte peroxidase.

A method of treating a tissue exhibiting eosinophil-related inflammation in a subject is disclosed. The method includes administering a composition to the subject that contains a therapeutically effective amount of a polymer and a pharmaceutically acceptable excipient. The polymer is formed from an acidic amino acid, e.g., aspartate and / or glutamate, or a pharmaceutically acceptable salt thereof. The polymer has an average molecular weight of at least about 5 kDa. The polymer binds to one or more eosinophil granule proteins in the tissue to neutralize the eosinophil granule proteins and treat the eosinophil-related inflammation.

The invention relates to the technical field of probiotics, in particular to an application of a probiotic (Bifidobacterium longum) in allergic asthma (preventing, relieving or treating allergic asthma). The invention relates to an application of probiotics in allergic asthma, in particular to an application of the probiotics in inhibiting a PI3K / AKT / NF-kappa B signal channel. According to the probiotics disclosed by the invention, activation of a PI3K / AKT / NF-kappa B signal channel is specifically inhibited, immune imbalance is regulated and controlled from the source, and Th2 type immune response is effectively inhibited. Specifically, the total IgE level in serum and the expression of Th2 type cytokines such as IL-4, IL-5 and IL-13 are remarkably reduced, the inflammatory response of the airway mainly caused by eosinophilic granulocyte infiltration is relieved, and the airway high reactivity and airway remodeling are effectively improved. The invention provides a novel intervention strategy which is clear in mechanism, high in safety and capable of treating both symptoms and root causes according to the intestine-lung axis theory, and has a wide application prospect in the aspect of treating allergic asthma.

The present invention relates to a reagent for detecting eosinophils, the application of eosinophils and their cytoplasmic contents and lipid metabolite hydroxydocosahexaenoic acid, belonging to the fields of medical treatment and pharmaceutical technology. The present invention provides the application of a reagent for detecting eosinophils in the preparation of a product for diagnosing pulmonary hypertension and / or judging the prognosis risk of pulmonary hypertension. By detecting the proportion of EOS in peripheral blood, the diagnosis of pulmonary hypertension and the judgment of the prognosis risk of pulmonary hypertension can be achieved.

The present invention provides an antibody comprising citrulline epitope or a binding fragment thereof for use in the treatment or prevention of a disease associated with release of an extracellular trap from a cell, such as a neutrophil extracellular trap (NET)-associated disease (NET-associated disease) or an eosinophil extracellular trap (EET)-associated disease (EET-associated disease), the method comprises administering at least one dose of an antibody at a specific concentration. The present invention also provides these methods themselves. NET related diseases include systemic lupus erythematosus (SLE), lupus, septicemia, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), sicca syndrome, antiphospholipid syndrome, Behcet's disease, spondylitis, spondyloarthropathy, multi-system atrophy, and the like. Parkinson's disease, Lewy body dementia, asthma, allergic rhinovirus aggravated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulogenic uveitis, granulogenic uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, and the like. Or other NET-related diseases, such as wound healing in diabetic patients, cancer, cancer metastasis, and transplanted organ health in vivo or in vitro. The invention also provides a pharmaceutical composition and a method for treating or preventing NET related diseases. Such as SLE, lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), sicca syndrome, antiphospholipid syndrome, Behcet's disease, spondylitis, spondyloarthropathy, multi-system atrophy, Parkinson's disease, Lewy body dementia, asthma, and the like. Allergic rhinovirus aggravated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulometric uveitis, granulometric uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, thrombotic disease, cardiovascular disease, and the like. Or other NET-related diseases, such as wound healing in diabetic patients, cancer, cancer metastasis, and transplanted organ health in vivo or in vitro. The EET-related diseases include eosinophilic granulocyte diseases or conditions, such as eosinophilic granulocyte diseases or conditions of skin; a respiratory eosinophilic granulocyte disease or condition; gastrointestinal eosinophilic cell diseases or disorders; allergic diseases or conditions; or worm, fungus, virus or bacterial infection.

The invention belongs to the technical field of biomedicine, and discloses an antibody for evaluating the curative effect of infantile pneumonia asthma and application of the antibody. The heavy chain CDR sequence of the monoclonal antibody (secreted by the hybridoma cell strain 2B5) is SEQ ID NO: 2-4, the light chain CDR sequence of the monoclonal antibody (secreted by the hybridoma cell strain 2B5) is SEQ ID NO: 6-8, the dissociation constant of the monoclonal antibody and an IL-5R antigen reaches 2.435 * 10 <-1 > / L, and the affinity is high. The antibody can accurately evaluate the curative effect of infantile pneumonia and asthma by detecting the lung function, the ratio of eosinophilic granulocytes in bronchoalveolar lavage fluid and lung tissue inflammation, can also significantly improve airway obstruction and inflammation of asthma model mice, has an effect superior to that of dexamethasone, solves the problems that existing curative effect evaluation is lack of specific tools and has large side effects of therapeutic drugs, and has good clinical application prospects. And a new scheme is provided for curative effect evaluation and adjuvant therapy of infantile pneumonia asthma.

The invention discloses an ABPA animal model building method which comprises the following steps: building an ABPA animal model by injecting a live aspergillus fumigatus spore suspension into an airway, and selecting a mouse for adaptive feeding; a primary sensitization stage; repeating the excitation stage; a live aspergillus fumigatus spore colonization excitation stage; and establishing an evaluation model. The animal model which highly simulates the pathophysiological characteristics of human ABPA is constructed by performing sensitization and excitation in stages and in multiple modes, especially by introducing the key step of lung colonization of live aspergillus fumigatus spores; through increase of serum total IgE and aspergillus fumigatus specific IgE levels, airway eosinophilic granulocyte infiltration and high secretion of mucus, the evaluation model is successfully constructed, and a reliable experimental platform is provided for deep analysis of pathogenesis of diseases.

The present invention belongs to the field of biomedicine, and relates to an anti-IL-5 antibody, a pharmaceutical composition thereof and the use thereof. Specifically, the present invention relates to an anti-IL-5 antibody or an antigen-binding fragment thereof. The anti-IL-5 antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises complementary determining regions HCDR1-HCDR3, and the light chain variable region comprises complementary determining regions LCDR1-LCDR3, wherein an amino acid sequence of HCDR1 is set forth in SEQ ID NO: 3, an amino acid sequence of HCDR2 is set forth in SEQ ID NO: 4, and an amino acid sequence of HCDR3 is set forth in SEQ ID NO: 5; and an amino acid sequence of LCDR1 is set forth in SEQ ID NO: 6, an amino acid sequence of LCDR2 is set forth in SEQ ID NO: 7, and an amino acid sequence of LCDR3 is set forth in SEQ ID NO: 8. The antibody of the present invention can specifically bind to IL-5, exhibits a high affinity, and has a good potential for treating or preventing diseases caused by eosinophils above the normal level.

The invention relates to the field of biological medicine, in particular to application of AREG in chronic sinusitis with nasal polyp eosinophilic inflammation. According to the invention, the nasal epithelial cell, especially the basal cell, is found for the first time, is a cell source of the AREG and is also one of important target cells acted by the AREG. AREG promotes proliferation of epithelial basal cells and inhibits differentiation of the basal cells into cilia cells, resulting in structural abnormality and function impairment of human CRSwNP tissue epithelial barriers. The AREG chemotactices and activates human peripheral blood eosinophilic granulocytes, and the receptor EGFR antagonist Erlotinib of the AREG can antagonize the effect of the AREG on the eosinophilic granulocytes. The AREG secreted by neutralizing epithelial cells or other inflammatory cells can effectively relieve the eosinophilic inflammatory reaction of the nasal mucosa of the CRSwNP mouse model and recover the damaged epithelial barrier function of the nasal mucosa of the mouse. It is proved that when the neutralizing antibody of AREG or EGFR or shRNA is used as the antagonist, the eosinophilic inflammatory response of CRSwNP can be relieved by inhibiting the effect of AREG.